ACP
GHDX

Aveo Capital Partners’s Genomic Health, Inc. GHDX Stock Holding History

Aveo Capital Partners’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,000
Closed -$588K – 240
2016
Q4 		$588K Buy
+20,000
New +$610K 0.17% 88

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aveo Capital Partners's GHDX Position: Q1 2017 in Review

Aveo Capital Partners sold out of Genomic Health, Inc. (GHDX) in Q1 2017, closing a stake of 20,000 shares — an estimated $588K sold.

Aveo Capital Partners first reported a position in GHDX in Q4 2016 and held it in 1 quarter. The position peaked at $588K in Q4 2016. 124 funds tracked by Wall St. Rank hold GHDX as of Q1 2017.

  • Aveo Capital Partners reported no remaining Genomic Health, Inc. position as of Q1 2017 after selling out during the quarter.
  • Aveo Capital Partners sold 20,000 Genomic Health, Inc. shares in Q1 2017, an estimated $588K.
  • Aveo Capital Partners first reported a position in Genomic Health, Inc. in Q4 2016 and held it in 1 quarter.
  • Aveo Capital Partners's Genomic Health, Inc. position peaked at $588K in Q4 2016.
  • 124 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2017.

Based on Aveo Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.